HIF-1, and more successfully HIF-2, are currently targets for anticancer drug development [4,5,6], and HIF-2 inhibitors have been tested in clinical trials and are now approved for therapy of tumours with constitutive HIF-2 activation from vHL mutation [7,8]. The gene discussed is HIF1A; the disease is neoplasm.